{"prompt": "['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'modifying listings of expected toxicities to include adverse events newly identified as', 'related to TEV-50717', '7.1.6.', 'Protocol-Defined Adverse Events of Special Interest', 'No protocol-defined adverse events of special interest were identified for this study.', '7.1.7.', 'Withdrawal Due to an Adverse Event', 'Any patient who experiences an adverse event may be withdrawn from the study or from study', 'treatment at any time at the discretion of the investigator or sponsor. If a post-baseline QTcF', 'value >500 msec or change from baseline >60 msec is found, the investigator should repeat the', 'ECG assessment twice and compare the average of the 2 pre-treatment QTcF values (baseline', 'and screening) to the average of the 3 post-baseline QTcF values. The IMP must be stopped for', 'any confirmed post-baseline QTcF value >500 msec or increase from baseline >60 msec. If a', 'patient is withdrawn wholly or in part because of an adverse event, both the adverse events page', 'and termination page of the CRF will be completed at that time.', 'In addition, a blood sample should be obtained for the measurement of IMP concentrations, if', 'possible. The patient will be monitored at the discretion of the investigator (eg, until the event', 'has resolved or stabilized, until the patient is referred to the care of a health care professional, or', 'until a determination of a cause unrelated to the IMP or study procedure is made). The', 'investigator must inform the clinical project physician/clinical leader as soon as possible of any', 'patients who are being considered for withdrawal due to adverse event(s). Additional reports', 'must be provided when requested.', 'If a patient is withdrawn from the study for multiple reasons that include adverse events, the', 'termination page of the CRF should indicate that the withdrawal was related to an adverse event.', 'An exception to this requirement will be the occurrence of an adverse event that, in the opinion', 'of the investigator, is not severe enough to warrant discontinuation but that requires the use of a', 'prohibited medication, thereby requiring discontinuation of the patient. In such a case, the reason', 'for discontinuation would be need to take a prohibited medication, not the adverse event.', '7.1.8.', 'Protocol Deviations Because of an Adverse Event', 'If a patient experiences an adverse event or medical emergency, deviations from the protocol', 'may be allowed on a case-by-case basis. To ensure patient safety, after the event has stabilized or', 'treatment has been administered (or both), the investigator or other physician in attendance must', 'contact the physician identified in the Clinical Study Personnel Contact Information section of', 'this protocol as soon as possible to discuss the situation. The investigator, in consultation with', 'the sponsor, will decide whether the patient should continue to participate in the study.', '7.2.', 'Psychometric Rating Scales', 'Site-administered safety scales include the MINI Kid and C-SSRS, and self-administered safety', 'scales include CDI-2.', '85']['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '7.2.1.', 'Mini International Neuropsychiatric Interview for Children and Adolescents', 'Select MINI Kid modules are administered at screening only. Children 13 years of age and under', 'may be interviewed separately or jointly with the caregiver/adult as appropriate or defined by the', 'scale. For children over 13 years of age, caregiver/adult involvement is strongly encouraged.', 'Questions should be directed to the child, but the caregiver/adult should be encouraged to add', 'relevant information.', 'The MINI Kid is a short questionnaire to be administered by a trained clinician. The MINI Kid', 'assesses symptoms of psychiatric disorders as outlined in the International Classification of', 'Diseases-10 and the DSM in children 6 to 17 years of age by self-report. For children under', '13 years old, the patient may be interviewed separately or jointly with the caregiver/adult as', 'appropriate or defined by the scale, and the caregiver/adult is encouraged to participate when', 'needed. The MINI Kid version 6 is composed of 24 modules overall, and questions are largely', 'yes-or-no questions. The current study will focus on 8 modules: Major Depressive Episode', '(Module A), (Hypo) Manic Episode (Module D), OCD (Module J), Alcohol Dependence/Abus-', '(Module L), Substance Dependence/Abuse (Non-alcohol; Module M), ADHD (Module O),', 'Conduct Disorder (Module P), and Psychotic Disorders and Mood Disorders with Psychotic', 'Features (Module R).', 'A reference sample is provided in Appendix C.', '7.2.2.', 'Columbia-Suicide Severity Rating Scale', \"The C-SSRS children's baseline/screening scale assesses past and current suicidal ideation and\", \"behaviors to determine suicide risk and is administered at screening. The C-SSRS children's\", 'SLV scale is administered at baseline and at weeks 2, 4, 6, 9, 12, and 13. Children 13 years of', 'age and under may be interviewed separately or jointly with the caregiver/adult as appropriate or', 'defined by the scale. For children over 13 years of age, caregiver/adult involvement is strongly', 'encouraged. Questions should be directed to the child, but the caregiver/adult should be', 'encouraged to add relevant information. The C-SSRS is an interview by trained study personnel.', 'Suicidal ideation', 'Patients with a positive C-SSRS suicidal ideation score on either items 1 or 2 or a change', 'on the CDI-2 Parent or Self-Report Profiles consistent with increasing depressive', 'symptoms must be 1) discussed with the medical monitor, 2) re-evaluated within 2 to 3', \"days in a clinic visit, and 3) treated according to the investigator's medical judgment.\", 'Consultation with a child and adolescent psychiatrist or licensed child/adolescent mental', 'health provider is advised, followed by close ongoing monitoring.', 'If patients endorse or report a C-SSRS suicidal ideation level of 3, 4, or 5, subjects will', 'be evaluated immediately by the study investigator and referred for psychiatric', 'evaluation. The medical monitor will be immediately consulted. If it is determined by the', 'investigator, after consultation with the medical monitor and the consulting psychiatrist,', 'that exposure to the IMP may have contributed to this change in C-SSRS and/or', 'increased depressive symptoms, IMP will be immediately discontinued and the patient', 'terminated from the study. In cases where it is determined that IMP did not contribute to', 'changes in depression or suicidality, the investigator will consult with the medical', '86']\n\n###\n\n", "completion": "END"}